Zhitong Financial App News, Huadong Pharmaceutical (000963.SZ) issued an announcement. On November 2, 2026, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“China-US Huadong”), a wholly-owned subsidiary of the company, received the “Notice of Acceptance” issued by the National Drug Administration (NMPA), and the marketing license application for oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist caverillone trometriol tablets (R&D code: HDM1002 tablets) for long-term adult weight control was accepted.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.